Taurine in Periodontitis and Aging

The Role of Taurine in Periodontitis and Aging: a Preliminary Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06635369

Enrollment

Registered

2024-10-10

Start date

2023-12-21

Completion date

2024-06-01

Last updated

2024-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Peridontal Disease

Keywords

Taurine, Periodontitis, Aging, Inflammation, TNF-α, SIRT1, Biomarker

Brief summary

Aging leads to a decline in physiological functions and increases the risk of chronic diseases. Periodontitis is a chronic inflammatory disease that causes progressive destruction of the tissues supporting the teeth. Taurine, an amino acid with anti-inflammatory and antioxidant effects, might impact both periodontitis and aging. This study investigated taurine, SIRT1, and TNF-α levels in saliva and blood of 66 healthy people in different age groups, with or without periodontal disease. The findings showed that young people with healthy periodontal status had higher levels of taurine and SIRT1 compared to others. TNF-α, a marker of inflammation, was linked to the severity of periodontitis and may help identifying it in younger individuals. Overall, higher TNF-α levels are associated with periodontal inflammation, while taurine levels decrease with age-related inflammation.

Interventions

DIAGNOSTIC_TESTPeriodontal Indices

Saliva, serum and periodontal indexes were obtained from patients

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

Participants are separated into four different groups. Young (25-44 years) with a healthy periodontium, young with periodontitis, old (≥65 years) with a healthy periodontium, and old with periodontitis

Eligibility

Sex/Gender

ALL

Age

26 Years to No maximum

Healthy volunteers

Yes

Exclusion criteria

* ages 18-25 or 45-64 * use of antibiotics, anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, or anticoagulants within the last 6 months * presence of diabetes, rheumatoid arthritis, or other systemic conditions such as cardiovascular, renal, hepatic, and neurodegenerative disorders * pregnancy or lactation * alcoholism * smoking * nonsurgical periodontal treatment in the past 6 months or surgical treatment in the past 12 months * having less than 20 natural teeth, excluding third molars * use of orthodontic appliances

Design outcomes

Primary

Measure	Time frame	Description
Taurine	12 Weeks	Taurine levels in saliva and serum were measured
SIRT1	12 Weeks	SIRT1 levels in saliva and serum were measured
TNF-α	12 Weeks	TNF-α levels in saliva and serum were measured

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026